Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 4/20 | 0.54 |
| ▸ | APP | P05067 | 2/20 | 0.50 |
| ▸ | F2 | P00734 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 5/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17236537 | 0.92 | APP (0.53) | ENPP2APPF2MAOBCYP4F2 | |
| SCHEMBL16687440 | 0.90 | ENPP2 (0.56) | ENPP2APPF2MAOBCYP4F2 | |
| SCHEMBL22315 | 0.90 | CYP4F2 (0.58) | ENPP2MAOBCYP4F2CYP4A11 | |
| SCHEMBL459524 | 0.89 | MAOB (0.60) | ENPP2MAOB | |
| SCHEMBL29952469 | 0.89 | MAOB (0.62) | ENPP2APPF2MAOB | |
| SCHEMBL23988 | 0.89 | NR4A2 (0.58) | ENPP2APPMAOB | |
| SCHEMBL22563 | 0.89 | ENPP2 (0.67) | ENPP2APPMAOB | |
| SCHEMBL15332207 | 0.85 | MAOB (0.67) | ENPP2APPMAOB | |
| SCHEMBL9964525 | 0.85 | MAOB (0.71) | APPMAOB | |
| SCHEMBL2557883 | 0.85 | RXRA (0.62) | ENPP2APPF2MAOBEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. (US) | 2015-12-24 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-8957049-B2 | Inhibitors of fatty acid amide hydrolase | INFINITY PHARMACEUTICALS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC. | 2011-07-14 | — | — | US | disclosed |
| WO-2009126691-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | INFINITY PHARMACEUTICALS, INC (US) | 2009-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172186-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ENPP2 68/4885APP 1081/4885F2 554/4885 |
| US-20150368278-A1 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE | FAAH, FAAH2, ASAH1 | ENPP2 68/4885APP 1081/4885F2 554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.